China Cell and Gene Therapy Manufacturing QC Market Size, Share & Trends Analysis Report By Therapy Type (Cell Therapy, Gene Therapy), By Scale (Pre-commercial/ R&D Manufacturing, Commercial Scale Manufacturing), By Mode (Contract Manufacturing, In-house Manufacturing), By Workflow (Cell Processing, Cell Banking, Fill & Finish Operations, Raw Material Testing, Vector Production, Other Workflows), By Process (Upstream Processes, Downstream Processes), By End-User (Pharmaceutical Companies, Biopharmaceutical / Biotechnological Companies, Contract Manufacturing Organizations), By Technology Type (Fluorescence-Activated Cell Sorting (FACS), Enzyme-Linked Immunosorbent Assay (ELISA), Chromatography, Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Others) and Forecasts, 2026-2034

China Cell and Gene Therapy Manufacturing QC Market Size

The China Cell and Gene Therapy Manufacturing QC Market size was valued at USD 824 million in 2025 and is projected to grow from USD 942.66 million in 2026 to USD 2765.42 million by 2034 at a CAGR of 14.4% during the forecast period 2026–2034.

In the past few years, with China's emphasis on innovation and the global rise in clinical trials involving these therapies, the country has become a key player in this sector. Additionally, the Chinese government's investment in biotech infrastructure and supportive regulatory framework has further accelerated the growth of this market.

Workflow Insights

Vector Production dominates the workflow segment and is expected to grow at a CAGR of 27.8%. The vector production workflow segment is expanding rapidly in the China Market, driven by the growing need for viral vectors in gene therapy. As gene therapies proliferate, efficient vector production with high-quality control is crucial for delivering accurate, safe, and effective genetic material to patients.

Request Customizationto receive a tailored report.

Process Insights

Upstream Processes dominates the process segment and is estimated to grow at a CAGR of 26.5%. The upstream processes segment in the Market is witnessing robust growth due to increasing demand for cell culture and gene editing techniques. Advances in bioreactor technologies and improved cell growth monitoring are driving efficiency, making upstream QC critical for scalable therapeutic production.

End User Insights

Biopharmaceutical/biotechnological companies are estimated to own the end-user segment and are anticipated to expand at a CAGR of 26.5%. Biopharmaceutical and biotechnological companies are the fastest-growing end-users in this market due to their central role in developing, manufacturing, and commercializing advanced therapies. With rising clinical trials and R&D investments, these companies require stringent QC measures to ensure compliance and product safety.

Speak to an Analystto discuss market opportunities.

Country Insights

China dominates the Asia-Pacific region due to its advanced biotechnology infrastructure, regulatory support, and clinical trial activity. The country's growing emphasis on biopharmaceuticals has made it the largest hub for cell and gene therapy research in Asia. The Beijing-Tianjin-Hebei region and the Yangtze River Delta are key areas driving market growth, with several biotechnology parks and government-funded research institutes located in these regions. Additionally, the Guangdong-Hong Kong-Macao Greater Bay Area is emerging as a major center for biotech innovation, supported by substantial government funding and favorable policies.

Furthermore, The NMPA's close collaboration with international regulatory bodies, including the FDA and EMA, ensures that China's QC standards for cell and gene therapies align with global benchmarks, further solidifying the country's position in the global Cell and Gene Therapy Manufacturing QC market. Moreover, there has also been a rise in the strategic initiatives of the key players to advance this technique technologically.

• For instance, in February 2023, Chinese startups Porton Advanced Solutions and Yinjia (Shanghai) Biosciences Co. declared a strategic alliance to develop essential protein raw materials for cell and gene therapy (CGT) and testing reagents for quality control and evaluation systems aimed at expediting the development and commercialization of CGT. Consequently, all these factors are estimated to drive the regional market expansion.

List of Key and Emerging Players in China Cell and Gene Therapy Manufacturing QC Market